Key Takeaways:
Japan's Takeda Pharmaceutical (4502.T) plans to cut about 4,500 jobs in fiscal year 2026 as it pushes ahead with a restructuring to centralize corporate functions and reduce costs, the company announced in its fourth-quarter earnings presentation.
"We are very, very excited about these three launches, and we’re laser-focused on the execution," CEO-Elect Julie Kim said on the company’s earnings conference call, referring to upcoming drug launches that are central to the company's growth strategy.
The company expects annual savings of more than 200 billion yen ($1.27 billion) by fiscal 2028, with about 100 billion yen expected in fiscal 2026. It anticipates restructuring costs of around 170 billion yen in fiscal 2026. Takeda's fiscal 2025 revenue was 4.51 trillion yen, down 1.7% from a year earlier.
The restructuring comes as Takeda grapples with declining revenues from its blockbuster ADHD drug Vyvanse, which is facing generic competition. The company is pinning its future growth on three new drug launches while continuing to streamline operations after its $62 billion acquisition of Shire in 2019, a deal that expanded its global footprint but also added significant debt.
The latest job reductions are part of a multiyear "transformation program" and follow a recent cut of 634 roles at the company's U.S. headquarters in Cambridge, Massachusetts. An earlier efficiency program impacted over 4,000 positions during the 2024-2025 period.
Takeda is preparing for a "new era" of growth acceleration, led by incoming CEO Julie Kim, who takes the reins next month. The company's strategy is focused on a "Horizon One" phase to establish new growth drivers and a "Horizon Two" to launch a new wave of late-stage pipeline assets. The company is making "decisive investments" to support regulatory filings for three key assets: oveporexton for narcolepsy, rusfertide for polycythemia vera, and zasocitinib for psoriasis.
Alongside the restructuring, Takeda also announced pipeline changes, discontinuing the development of its nausea and vomiting drug candidate, TAK-004, for strategic reasons. This follows a series of setbacks in the same therapeutic area in recent years.
The guidance for significant job cuts signals management's focus on long-term profitability ahead of a crucial period of new product launches. Investors will be watching the execution of these launches closely, with the first potential U.S. commercial launches for oveporexton and rusfertide anticipated in the second half of 2026.
This article is for informational purposes only and does not constitute investment advice.
